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Parkinson’s disease has multiple determinants and is
associated with a wide range of exposures that appear
to modify risk in traditional observational studies,
including numerous lifestyle and environmental factors.
Across other fields of medicine, Mendelian randomiza-
tion has emerged as a powerful method to examine
whether associations between exposures and disease
outcomes are causal. Here we discuss the concept of
Mendelian randomization, its potential relevance to Par-
kinson’s disease, and suggest avenues through which
the method could be employed to further understanding
of the causal basis of Parkinson’s disease. VC 2015 Inter-
national Parkinson and Movement Disorder Society
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Two decades ago, Parkinson’s disease (PD) was
thought to be an entirely sporadic disorder with little,
if any, genetic component. Despite identification of
monogenic forms of disease (such as mutations in
SNCA, LRRK2, PINK1, PARK2, and DJ-1)1-3 and
genetic risk factors for PD (such as mutations in
GBA),4-6 this is a prevailing view held by some clini-
cians and much of the patient community. Up to 10%
of patients report a family history of PD,7 but family
history is different from heritable genetic risk. The
genetic architecture of PD is complex, and genetic var-
iability likely accounts for a large proportion of the
heterogeneity of PD, even if much of this currently
remains unexplained. Conservative heritability esti-
mates attributable to common genetic risk in PD are
approximately 30%, even in sample series with only
limited family history.8
The monogenic forms of PD, identified through can-
didate gene studies, are individually sufficient to cause
PD, but account for a small proportion of PD caseload
overall (5%).2 Separately, genome-wide association
studies (GWAS) have identified common, low-effect
variants that account for additional heritability, each
potentially acting in a small but additive fashion, and
28 independent susceptibility loci for PD have been
reported.9 Meta-analyses of GWAS have supported
some of the findings of candidate gene work and pro-
vided estimates of effect size for a range of variants,
with some of the larger ones being LRRK2 (odds ratio
[OR] for G2019S mutation, 9.62; 95% confidence
interval (CI), 6.43-14.37)10 and GBA (N370S muta-
tion OR, 3.51; 95% CI, 2.55-4.83).11
Environmental risk factors for PD have tended to be
associated with small effect sizes in observational stud-
ies (OR, 1.2-1.8).12 In some cases even these may
have been artificially inflated by bias and/or confound-
ing (see Fig. 1). Confounding by prevalent disease
(reverse causality) is a particular problem for many
factors associated with reduced risk of PD, including
cigarette, coffee, and alcohol consumption, given that
patients may exhibit specific personalities in the years
before diagnosis.13 Thus, apparent temporal associa-
tions with exposures may have been identified, when
in fact they are indicative of prodromal or
------------------------------------------------------------
This is an open access article under the terms of the Creative
Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly
cited.
*Correspondence to: Dr. Alastair J Noyce, Reta Lila Weston Institute,
UCL Institute of Neurology, 1 Wakefield Street, London, UK, WC1N 1PJ,
E-mail: a.noyce@ucl.ac.uk
Funding agencies: Not applicable.
Relevant conflicts of interest/ Financial disclosures: Both authors
report no direct conflicts of interest relating to this work.
Received: 8 April 2015; Revised: 20 October 2015; Accepted: 25
October 2015
Published online 00 Month 2015 in Wiley Online Library
(wileyonlinelibrary.com). DOI: 10.1002/mds.26492
V I E W P O I N T
Movement Disorders, Vol. 00, No. 00, 2015 1
prediagnostic disease, rather than being causally
related. This issue may have applied to cohort studies
that excluded incident cases within the first few years
of follow-up because the prodromes of PD are likely
to be very long.14 For factors that are associated with
elevated risk of PD, such as head injury caused by fall-
ing because of undiagnosed prevalent disease (as
opposed to historical sports or combat-related inju-
ries), the same might apply. The biases of retrospective
case-control studies are well recognized, including
but not limited to recall bias, selection bias, and
observer bias.
Thus, when inferring causality, well-conducted
randomized controlled trials (RCTs) sit at the head of a
hierarchy, superior to observational study designs,
which follow beneath. If sample sizes are large, the pro-
cess of allocating an exposure (intervention or drug) to
patients on a sufficient scale, randomly and evenly
FIG. 1. Genetic (yellow) and nongenetic (orange) risk factors, their influence on phenotype (red), and where confounding, bias and reverse causality
can arise (blue). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
TABLE 1. Recognized risk and protective factors for PD,12 the nature of association, and limitations when considering
randomized controlled trials
Factor Evidence
Association
with risk of PD Problem(s) with assessing causal effect using RCT design
Smoking 111 Protective Negative effects on wider health
Alcohol 111 Protective Negative effects on wider health
NSAIDs 11 Protective Difficult to prevent subjects in placebo arm from using over-the-counter
forms
Statins 11 Protective None — investigational medicinal product in an RCT (personal communi-
cation with principal investigator)
CCBs 111 Protective None — investigational medicinal product in an RCT (clinicaltrials.gov ref-
erence NCT02168842)
Coffee 111 Protective Difficult to prevent subjects in placebo arm from consuming
Pesticides 111 Increase risk Heterogeneous, measurement
Head injury 111 Increase risk Reverse causality (ie, head injury from falls), long lag time (ie, head injury
from sports)
Obesity 1/- Increase risk Measurement, masking by prevalent disease, negative effects on wider
health
Heavy metals 1/- Increase risk Heterogeneous, measurement
Iron — investigational medicinal product in an RCT (clinicaltrials.gov refer-
ence NCT01539837)
Low serum urate 11 Increase risk Under investigation (clinicaltrials.gov reference NCT00833690)
111Meta-analysis of observational studies; 11multiple observational studies suggesting directionality of effect; 1/-conflicting data from single studies. RCT,
randomized, controlled trial; PD, Parkinson’s disease; NSAID, nonsteroidal anti-inflammatory drugs; CCB, calcium channel blockers.
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distributes known and unknown confounding factors,
meaning that any effect observed can be attributed to
causal influence. Furthermore, the effect is free from
reverse causality and sheltered from bias (as long as the
selection process and blinding have been optimized).
Opportunities to use RCTs to study causal relation-
ships between environmental exposures and PD are
limited by the ethical and logistical challenges they
pose (see Table 1). For example, it is not acceptable to
expose subjects to smoking and pesticides for the pur-
pose of causal inquiry, and it is difficult to ensure that
randomization to nonsteroidal anti-inflammatory
drugs (NSAIDs) versus no NSAIDs would be upheld
when they are available over the counter.
In other fields of medicine, Mendelian randomiza-
tion (MR) has emerged as a technique for gaining
greater understanding of the role that environmental
exposures play in disease causation.15,16 Here genetic
variants are used as so-called ‘instrumental variables’
that reflect a particular environmental exposure by vir-
tue of attesting to, in a dose-dependent manner, differ-
ential exposure status (for example, a genetic variant
associated with obesity may convey an increase in
body mass index per allele inherited). Alleles are allo-
cated at conception and operate with long-lasting
effects, which negate the risk of reverse causality.
However, gene expression may vary through life,
meaning that detailed biological understanding can
hugely enhance inferences made from MR. Random
assortment during meiosis can be seen as equivalent to
the randomization process in a well-conducted RCT;
moreover, the random allocation of all other genetic
material is akin to the random distribution of known
and unknown confounding variables alongside expo-
sure status. The causal inference that can be drawn
from a well-conducted MR study sits below that of
well-conducted RCTs and above observational study
designs, as long as limitations are recognized
and understood (see Table 2 for advantages and
disadvantages).
A number of criteria17 must be satisfied to identify
genetic variants as suitable instrumental variables for
environmental exposures (depicted in Fig. 2):
1. The genetic variant must be robustly associated
with the exposure.
2. The genetic variant must be independent of
known confounders.
3. For a known exposure and known confounders,
the genetic variant must be independent of the out-
come (known as the exclusion restriction criteria).
In other words, there must no alternative route,
other than via the exposure, that the instrumental
variable is associated with the outcome.
TABLE 2. Advantages and limitations of MR in inferring causality (adapted from Lawlor et al16)
Advantages Disadvantages and limitations
Random allocation of genetic variant of interest (and therefore exposure)
— avoids selection bias and is synonymous with methods used for
traditional RCTs.
Pleiotropy — horizontal pleiotropy describes the situation in which a
genetic variant affects the outcome via a different pathway from the
one that includes the exposure under investigation and may result in
bias. There are ways to avoid/negate pleiotropy, such as the selection
of multiple instrumental variables, or correct the bias that it creates,
such as the use of MR-Egger.26
Random allocation of confounders — also avoids selection bias and evenly
distributes confounding factors between exposed and unexposed (as per
traditional RCTs).
Population stratification — different populations may have different rates
of disease (outcome of interest) and/or different distributions of genetic
variants (exposure of interest), resulting in biased effect estimates.
Blinding — patient does not know his/her genetic variant (exposure) status
and therefore behavior is unlikely to be affected (as per traditional
RCTs).
Linkage disequilibrium (LD) — gene loci are presumed to be independent
of one another, but LD describes the situation in which they are not;
genetic variants may be coinherited, and bias can result. This can cre-
ate a situation in which horizontal pleiotropy or confounding occurs.
However, in some instances, LD is an advantage and allows an
unmeasured variant, which influences the exposure of interest, to be
estimated through use of a measured gene variant as a proxy.
Life-long exposure — effects may be exerted throughout life as long as
expression not differential (significant advantage over traditional RCTs).
Canalization — describes developmental compensation to neutralize the
effect of a particular genotype on a disease outcome, but not necessar-
ily the association with the exposure. This may significantly weaken the
instrumental variable and bias estimates.
Ethically sound — allows study of the potential effect of exposures that
are not appropriate for traditional RCTs ie, smoking.
Statistical power — the magnitude of effect that allelic increases have on
an environmental exposure is often very small (and may be tiny if the
instrument is weak). This means that sample sizes must be very large.
Cost effective — compared with RCTs or prospective cohort studies. MR
studies can often be conducted in situations in which much of the data
(genetic and clinical) has already been collected.
Adequate biological understanding — detailed information is required
about the effects of the variant of interest, conditions under which it is
expressed, or conditions that alter expression to make inferences about
causality.
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Searching the Medline database provides sparse
examples of the use of MR in PD (3 articles found
using the search terms “Mendelian randomization”
and “Parkinson’s disease”) and, indeed, all neurologi-
cal disease to date, apart from those undertaken in the
study of stroke.18,19 However, a group recently
reported observations from an MR study in subjects
with PD. The a priori hypothesis was that, consistent
with findings from observational studies, low serum
urate was associated with increased risk of PD. The
authors hypothesized that polymorphisms that predict
serum urate levels would also predict rate of clinical
progression in subjects with early PD from the PRE-
CEPT and DATATOP studies. They selected single-
nucleotide polymorphisms (SNPs) within the SLC2A9
gene, which explains most of the genetically specified
variance in serum urate, and a dose-dependent reduc-
tion in serum urate for increasing allele counts was
observed.20 There was weak evidence for an increased
rate of disease progression, defined as disability requir-
ing dopaminergic treatment (increasing SLC2A9 score
HR, 1.16; 95% CI, 1.00-1.35; P5 0.06). Directionality
of effect was consistent between measured decreases in
serum urate or genetically conferred decreases. Stron-
ger effects may have been masked by the choice of
outcome and the modest sample size of 800 subjects,
but these results increase confidence that targeting ele-
vations in urate may be a plausible approach in neuro-
protective studies in PD. Other studies have previously
considered genetic influence on serum urate levels and
PD risk, as well as interactions between variants and
environmental factors, but not specifically adopting
MR approaches.21,22 These may have violated some of
the inherent assumptions of MR, have been under-
powered, or require further replication.
Separately, a group reported observations relating to
serum iron and PD, using data from PD GWAS.23
Three genetic variants were used as instrumental vari-
ables (HFE rs1800562, HFE rs1799945, and
TMPRSS6 rs855791) and were associated with serum
iron levels (accounting for 1.7%, 0.9%, and 1.7% of
iron total variance, respectively). Each variant con-
veyed an increase of iron level per allele of between
7.1 and 13.9 mg/dL. The polymorphism in TMPRSS6
alone was associated with reduced risk of PD OR of
0.97 (95% CI, 0.94-0.99; P50.034). Meta-analysis to
determine a pooled effect size across these 3 variants
gave an OR of 0.88 (95% CI, 0.82-0.95; P5 0.001)
for the reducing the OR for PD per SD unit increase
in iron, consistent with a protective effect.
In an exploratory study, another group used SNPs
from the CHRNA3-CHRNA5-CHRNB4 gene cluster
known to be associated with smoking behavior to
assess associations with PD.24 Although no effect on
PD was found, the sample sizes were moderate, and the
study may have been underpowered to detect an effect.
These examples introduce some of the potential lim-
itations of MR, which include pleiotropy and statisti-
cal power. Horizontal pleiotropy describes the
situation in which a genetic variant has multiple inde-
pendent effects that do not lie on a single pathway,
meaning that instrumental variable assumptions may
be violated (see Table 2). Previously, use of multiple
gene variants known to operate via the same interme-
diate phenotype (such as the example above from
Pichler and colleagues23) and finding similar effect size
estimates and absence of heterogeneity offered some
evidence against pleiotropy.25
Post-GWAS, increasingly, MR studies use multiple
genetic variants to improve precision of causal effect
estimates. This in turn can increase the risk of hori-
zontal pleiotropy and bias. Adaptation of traditional
meta-analysis methods such as funnel plots to detect a
difference in effect estimates because of weaker var-
iants and MR-Egger (based on Egger regression used
to assess small-study bias in meta-analyses) can be
used to detect and adjust for pleiotropy arising
through multiple variant analysis.26
Away from pleiotropy, MR studies need to be suffi-
ciently powered so that causal hypotheses may be
adequately tested. At least 2 of the 3 MR studies in
PD listed above may have been underpowered because
of moderate sample sizes and may have failed to reject
the null hypothesis, when in fact a real effect was
present (type 2 error). Additional limitations include
population stratification, canalization and adequate
understanding of the underlying biology (all described
in Table 2 along with potential implications).
Special reference should be made to the potential
implications of linkage disequilibrium (LD). Gene loci
are presumed to be independent of one another, but
LD describes the situation in which they are not, and
therefore genetic variants may be coinherited. Loss of
independence is not exclusively a result of the proxim-
ity of loci, and coinheritance can occur despite loci
FIG. 2. Directed acyclic graph (DAG) demonstrating the concept and
assumptions of Mendelian randomization (with an example in paren-
theses), including the relationship of the instrumental variable with the
exposure (assumption 1) and independence from confounding factors
(assumption 2) and the outcome (assumption 3). Note that the only
way that the instrumental variable influences the outcome is via the
exposure (behavior or phenotype). In the example given, the FTO
gene variant (instrumental variable) influences BMI (exposure/interme-
diate phenotype), which is causally associated with heart disease (out-
come). [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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being physically distant from one another. It is easy to
see how this situation could negatively affect MR
studies; however, this is not always the case, and
many MR studies use LD to their advantage, using a
measurable variant as proxy for an unobservable vari-
ant that influences the modifiable exposure. In other
situations, LD can cause confounding and induce plei-
otropy, which may in turn violate instrumental vari-
able assumptions. The relevance of LD in MR studies
has been discussed elsewhere and examples pro-
vided,16 but in summary, LD needs to be understood
within the context of individual MR studies before
deciding how it ought to be handled.
In many instances, there may not yet be sufficient var-
iance explained by recognized gene variants to allow an
MR approach to be undertaken for certain potentially
modifiable exposures. However research in PD genomics
moves forward with great momentum, and the onus to
provide robust instrumental variables for modifiable
behaviors such as smoking and alcohol use comes from
even more powerful spheres of cardiovascular and can-
cer research. Within specific MR studies, the magnitude
of association between the instrumental variable and the
exposure ought to be established at the outset and con-
firmed to be consistent with estimates from independent
studies. In addition, traditional confounders of the rela-
tionship between exposure and the outcome, should be
described for each gene variant used in the study and
shown to be no different between them rather like the
baseline characteristics table used when reporting an
RCT. In carrying out the MR study, it may be important
to be able to compare the effect that the gene variant has
on the outcome (via the exposure), with the effect that
the directly measured exposure has on the outcome in
the same cohort. Effects operating in the same direction
give credence to the results from observational studies,
whereas opposing effects are likely to warrant further
investigation. The methodological approaches for
undertaking MR studies are varied and numerous, and
have been recently described.27
At present there exist a number of options to exploit
MR and understand more about the variance of PD
attributable to modifiable exposures (examples are
listed in Table 3). For all the examples given, there
exists extensive observational study literature and for
caffeine, some limited RCT data.28 In addition, each
of these factors has potential instrumental variables
available, and MR could significantly advance under-
standing of their causal association with PD.
Traditional RCTs have their own limitations, includ-
ing high cost and resource requirements, and in the
context of PD, long follow-up and in some cases
impracticality. Hence, large-scale prospective, observa-
tional studies and/or the mining of medical records
and biosamples from massive health systems with elec-
tronic medical records could act as an in silico labora-
tory for MR studies and function much like an RCT
with comparatively minimal bias. The key issue here
is the quality and depth of phenotypic data available,
the absence of which to-date has meant limited
attempts to make genotype-phenotype assertions in
large-scale studies, with analyses restricted to compar-
ing cases versus controls or genetic risk profiles for
intermediate phenotypes and not the phenotypes them-
selves.29 We propose that in the context of improving
phenotypic data and refining identification of func-
tional genetic variants, focusing some resources to the
field of MR could help to drive the understanding of
PD causality significantly further forward.
Summary
Other fields of medicine have seen a rapid expansion
in the use of MR for etiological inquiry. We believe
that MR has great potential to be used to further
explore the causal basis for a variety of exposures and
associations with PD that have been reported in obser-
vational studies. Many of these exposures do not natu-
rally lend themselves to traditional RCTs because
these would be considered unethical. However, confir-
mation of direction and magnitude of effects in MR
studies with those from observational studies may
prompt further consideration of these factors as tar-
gets for intervention and potentially disease modifica-
tion.
Acknowledgements: A.J.N. is funded by Parkinson’s UK (grant
reference F-1201).
TABLE 3. Examples of variants that could be further explored as instrument variables to ascertain causal association of
environmental factors and PD
Factor Candidate variant examples Anticipated effect
Smoking rs1051730, rs4105144, rs6474412, rs8034191,
rs17486278, rs569207, rs16969968, rs578776,
rs649530824,30
Reduce/increase smoking quantity,
increase/reduce risk of PD
Coffee rs2472297-T, rs6968865-T31 Increase coffee consumption, reduce risk of PD
Alcohol Alcohol dehydrogenase 1B gene (ADH1B)19 Reduce alcohol consumption, increase risk of PD
Obesity FTO gene rs9939609 polymorphism32 Elevate BMI, increase risk of PD
Example variants identified from published literature and National Human Genome Research Institute (NHGRI) catalogue.
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